News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Says New Bleeding Cases Found In Pradaxa Study


5/15/2014 11:43:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Boehringer Ingelheim GmbH said a new analysis of a company-funded study used to win approval of the blood thinner Pradaxa found 22 serious bleeding events that weren’t included in the original report. Additional events were found in patients in each of the three arms of the 18,000-patient study known as RE-LY. Five more complications were seen among those taking a 110-milligram dose of the drug, 11 among those on a 150-mg dose and six in the patients using warfarin. Pradaxa became the first alternative to warfarin, the standard of care for more than five decades for preventing strokes caused by blood clots, when it was approved in 2010 by the U.S. Food and Drug Administration.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

Related News

comments powered by Disqus
Bloomberg
   
Bleeding

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES